News

Ziopharm has reported that the enrollment in the palifosfamide (Zymafosk or ZIO-201) phase II trial in metastatic or unresectable soft tissue sarcoma, continues in a planned manner. Reportedly,

Shin-Etsu Chemical has completed the procedures required to make its affiliate CIRES a wholly-owned subsidiary of Shin-Etsu. Earlier in December 10, 2008, Shin-Etsu announced its plan to make

Cortex has reported a net loss of $2.7m, or $0.06 per share for the quarter ended June 30, 2009, compared to a net loss of $3.9m, or $0.08

Hard to Treat Diseases (HTDS Medical) has reported the progress being made with the experimental findings to aid in the suppression or ultimately the cure of Multiple Sclerosis,

Glancy Binkow & Goldberg, a law firm has filed a class action complaint in the US District Court for the Southern District of Texas on behalf of a

Barr Laboratories has initiated a voluntary recall of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate 20mg tablets, 100 count bottles, lot number 311756. The product is

Centrix, a specialty pharmaceutical company focused on Pediatrics and Women’s Health, is all set to launch Clofera during the fourth quarter. Clofera is indicated for the temporary relief

Tiens Biotech Group’s revenue for the second quarter of 2009 increased 4.6% to $20.6m, compared to $19.7m for the second quarter of 2008. For the six months ended

Rollprint, packaging products company, announced that the prototype laboratory can help cut time to market by providing information about how packaging will behave in the commercial environment, reported